Miragen therapeutics, inc. (MGEN)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities:
Net loss

-8,044

-10,118

-11,230

-8,896

-11,629

-10,317

-9,011

-8,714

-4,661

-6,386

-5,834

-7,312

-6,980

-5,974

-4,153

-3,524

-3,623

-2,980

-3,152

-2,562

-2,634

-3,508

-387

-3,289

-706

Adjustments to reconcile net loss to net cash used in operating activities:
Unpaid common stock issuance costs included in prepaid expenses and other assets, accounts payable, and accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Issuance of common stock under subscription agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

330

-

-

-

-

Share-based compensation expense

664

1,003

874

1,075

1,018

937

968

984

790

716

679

595

419

69

45

42

42

757

838

712

708

-

-

-

-

Implementation of ASC 842 and other non-cash lease expenses

75

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

63

74

80

92

94

93

94

93

96

9

24

29

32

33

42

41

42

-

-

-

-

-

-

-

-

Depreciation and amortization

100

85

115

27

73

100

62

69

69

73

79

75

73

88

88

84

81

47

47

45

45

38

34

36

36

Loss on sale of equipment

-11

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of premiums and discounts on available-for-sale securities

1

22

85

143

182

187

168

61

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Noncash interest on note payable  related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

22

22

68

20

-1

0

476

532

Changes in operating assets and liabilities:
Accounts receivable

-104

-871

654

319

-18

-1,358

184

-3,611

3,353

821

96

262

257

11

-729

798

-60

-153

-34

-17

-490

-462

191

185

180

Inventory

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-177

-172

206

151

-53

39

68

-232

Prepaid expenses and other assets

-436

-612

-458

646

298

-978

81

325

521

5

451

-266

534

-119

105

377

63

-199

276

-1

-104

-181

-35

336

-311

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-80

-93

-173

-173

-

-

-

-

-

-

-

-

Accounts payable

410

-460

324

715

-54

-622

732

-299

-146

497

-200

-516

118

878

-768

-53

235

-

-

-

-

-

-

-

-

Accrued and other liabilities

-2,245

161

895

877

-849

-490

780

136

365

-1,334

136

47

-1,054

1,318

1,380

284

-771

-

-

-

-

-

-

-

-

Accounts payable and accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

326

74

-168

401

-21

326

69

9

Lease termination/abandonment payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

63

93

92

71

62

94

149

Net cash used in operating activities

-8,459

-7,806

-9,267

-7,174

-11,809

-8,175

-6,802

-4,506

-7,361

-7,243

-5,663

-7,078

-8,183

-3,287

-2,835

-4,463

-4,170

-1,299

-2,304

-2,186

-1,109

-997

-831

-470

85

Cash flows from investing activities:
Purchases of short-term investments

0

0

3,964

4,943

23,783

23,858

5,809

32,795

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of short-term investments

2,000

7,000

15,000

18,000

21,000

33,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash acquired in reverse merger

-

-

-

-

-

-

-

-

-

0

0

0

1,280

0

0

0

0

-

-

-

-

-

-

-

-

Proceeds from sale of property and equipment

1

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property and equipment

0

0

15

32

37

51

205

94

95

34

63

105

44

10

24

111

105

23

32

24

44

-

-

-

-

Net cash provided by (used in) investing activities

2,001

7,000

11,021

13,025

-2,820

9,091

-6,014

-32,889

-95

-34

-63

-105

1,236

1,000

2,975

-4,120

-105

-23

-4

-24

-44

-

-

-

-

Cash flows from financing activities:
Proceeds from the sale of common stock and warrants

19,754

-

-

-

138

-

-

-

-

-

-

-

-

-

-

0

0

0

4,021

-272

9,346

0

-469

7,387

-274

Payment of issuance costs associated with the sale of common stock

1,068

-

-

-

4

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Payments of principal on note payable

1,000

1,000

1,000

333

0

-

-

-

-

3,167

500

500

500

333

0

0

0

-

-

-

-

-

-

-

-

Proceeds from stock purchases under employee stock purchase plan

16

0

26

0

84

0

132

0

110

0

110

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from Stock Options Exercised

13

15

70

15

0

21

33

34

112

80

72

59

89

213

0

0

0

-

-

-

-

-

-

-

-

Proceeds from issuance of note payable/amounts due to related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

695

100

Shares repurchased to satisfy tax withholding obligation for restricted stock awards

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

17

319

27

-

-

-

-

Repayment of capital lease obligation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

20

20

19

17

11

-1

17

15

Net cash provided by financing activities

17,715

795

-904

-39

218

-10

1,114

2,698

38,114

11,913

2,196

-755

39,116

-207

16,081

0

0

30

3,984

-610

9,302

-11

-468

8,065

-189

Net increase (decrease) in cash and cash equivalents

11,257

-

-

-

-14,411

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-3,530

-7,938

32,169

-2,494

16,221

-8,583

-4,275

-1,292

1,676

-2,820

8,149

-1,269

-1,308

7,591

-104

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-11,702

-34,697

30,658

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosure of cash flow information
Cash paid for interest

61

105

129

141

136

131

126

120

112

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

39

38

40

42

41

41

-

-

-

-

-

-

-

-

Supplemental disclosure of non-cash investing and financing activities
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, before Tax

-

-

-

-

-

3

-10

4

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of public offering costs

30

2

0

0

1

0

1

7

47

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized Gain (Loss) on Investments

0

-

-

-

5

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unpaid common stock issuance costs included in current liabilities

-

-

-

-

-

-

-

-

-

-

-54

-167

224

-

-

-

0

-

-

-

-

-

-

-

-

Conversion of preferred stock to common stock

-

-

-

-

-

-

-

-

-

0

0

0

76,981

0

0

0

0

-

-

-

-

-

-

-

-

Liabilities assumed, net of non-cash assets received in reverse merger

-

-

-

-

-

-

-

-

-

0

0

0

1,076

0

0

0

0

-

-

-

-

-

-

-

-

Transfer of common stock issuance costs from prepaid expenses and other current assets to equity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Reclassification of preferred stock warrant (accrued liability) to common stock warrant (equity)

-

-

-

-

-

-

-

-

-

0

0

0

51

0

0

0

0

-

-

-

-

-

-

-

-

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

0

0

0

5

12

13

12

12

-

-

-

-

-

-

-

-

At-the-market
Proceeds from the sale of common stock

-

-

-

-

-

-

1

2,746

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of issuance costs associated with the sale of common stock

-

-

-

-

-

-

0

82

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Public offering
Proceeds from the sale of common stock

-

-

-

-

-

-

0

0

40,782

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of issuance costs associated with the sale of common stock

-

-

-

-

-

-

0

0

2,890

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-